REFRACTORY CANCER
Clinical trials for REFRACTORY CANCER explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CANCER trials appear
Sign up with your email to follow new studies for REFRACTORY CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune drug IMA401 takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug called IMA401 in about 95 adults with advanced solid tumors (like lung or head/neck cancer) that came back or didn't respond to prior treatments. IMA401 is a special immune molecule that helps the body's T cells attack cancer cells. The stu…
Matched conditions: REFRACTORY CANCER
Phase: PHASE1 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated May 17, 2026 04:28 UTC
-
New drug targets tough cancers in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called 9-ING-41, which blocks a protein (GSK-3β) that helps cancers grow. It is given alone or with chemotherapy to 350 adults with advanced or hard-to-treat cancers like pancreatic, breast, lung, or bone cancer. The goal is to see if the dru…
Matched conditions: REFRACTORY CANCER
Phase: PHASE2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated May 17, 2026 04:26 UTC
-
Tailored cancer therapy tested for patients who've run out of options
Knowledge-focused OngoingThis study explores whether personalized treatment recommendations based on lab tests of a patient's own tumor can be made within 4 weeks for adults with relapsed or refractory cancers who have no standard curative options. Researchers will use drug sensitivity testing and geneti…
Matched conditions: REFRACTORY CANCER
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 04:17 UTC